From: Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis
Effect
Estimate (95 % CI)
p-value
Disease duration
−0.9 (−1.4 to −0.4)
0.0046
Drug, abatacept vs. placebo
−9.8 (−16.7 to −3.0)
0.0114
Study visit
−0.1 (−1.2 to 0.9)
0.783
Study visit abatacepta
−0.9 (−2.2 to 0.4)
0.1773